Inflammasome, T Lymphocytes and Innate-Adaptive Immunity Crosstalk: Role in Cardiovascular Disease and Therapeutic Perspectives

Daniela Pedicino1,* Ada Francesca Giglio1,* Aureliano Ruggio1 Gianluca Massaro1 Alessia D’Aiello1 Francesco Trotta1 Claudia Lucci1 Francesca Graziani1 Luigi Marzio Biasucci1 Filippo Crea1,** Giovanna Liuzzo1,**

1Department of Cardiovascular and Thoracic Sciences, IRCCS-Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome, Italy

Address for correspondence Giovanna Liuzzo, MD, PhD, Department of Cardiovascular and Thoracic Sciences, IRCCS-Fondazione Policlinico Universitario A. Gemelli, Largo A. Gemelli, Catholic University of the Sacred Heart, 8–00168 Rome, Italy (e-mail: giovanna.liuzzo@gmail.com).

Introduction

The immune system consists of two different, tightly connected arms, which guarantee both immediate and long-term immunity to pathogens. Complement, pattern recognition receptors (PRRs), anti-microbial proteins and phagocytes are the main mediators of innate immune system, acting as the first step in immune responses, then inducing and regulating the second arm of adaptive immunity. B- and T-lymphocytes, the key elements of adaptive immunity, are involved in long-term immune response to foreign and, in some cases, self-antigens, so their activation needs to be tightly regulated to avoid chronic inflammatory and autoimmune diseases. The role of innate immune responses in the onset and progression of coronary artery disease (CAD) has been widely documented, together with an adaptive immunity imbalance, mostly involving T cell sub-sets. The aim of this review is to discuss whether and how the inflammation is able to influence adaptive immunity response and T cell sub-set differentiation, being part of the immune dysregulation leading to atherosclerosis and plaque instability.1–3

Keywords
► precision medicine
► inflammasome
► innate immunity
► adaptive immunity
► coronary artery disease
► acute coronary syndromes

Abstract

Over the past few decades, lot of evidences have shown atherosclerosis as a chronic progressive disease with an exquisite inflammatory feature. More recently, the role of innate immune response in the onset and progression of coronary artery disease (CAD) and an adaptive immunity imbalance, mostly involving T cell sub-sets, have been documented. Therefore, like in many other inflammatory and autoimmune disorders, an altered innate-adaptive immunity crosstalk could represent the key of the inflammatory burden leading to atherosclerotic plaque formation and progression and to the breakdown of plaque stability. In this review, we will address the role of inflammasome in innate immunity and in the imbalance of adaptive immunity. We will discuss how this altered immune crosstalk is related to CAD onset and progression. We will also discuss how unravelling the key molecular mechanisms is of paramount importance in the development of therapeutic tools to delay the chronic progression and prevent the acute destabilization of atherosclerotic plaque.
**Inflammasome Mediators: PRRs, Caspase-1 and Interleukin-1β**

‘Inflammasome’ is a macro-molecular complex whose activation, after recognition of microbial and/or cell damage signals, results in the cleavage and activation of caspase-1, with subsequent secretion of interleukin (IL)-1β and other pro-inflammatory cytokines. The key mediators and the different types of inflammasome known to date are described in the following paragraphs (see -Tables 1 and 2 for a classification of human receptors involved in inflammasome activation). 4–6

**PRRs and Inflammasome Forming Proteins**

Over the past 15 years, our understanding of the molecular mechanisms regulating the innate immune system has dramatically changed based on the identification of the PRRs, germ-line-encoded key receptors able to identify ancestral motifs and signatures of potential harmful agents. 7 Toll-like receptors (TLRs), expressed on cell surface and endosome’s membranes, mostly sense microbial products (pathogen-associated molecular patterns), while nucleotide oligomerization domain-like receptors (NLRs), retinoic acid inducible gene I-like receptors and absent in melanoma 2 (AIM2)-like receptors function as pathogen sensors in intra-cellular compartments. Through these intra-cellular receptors, the innate immune system recognizes also a class of signals in the form of cellular stressors, collectively termed ‘danger signals’ or danger-associated molecular patterns (DAMPs). NLRs and AIM2 take part to the assembling of the inflammasome, and NLRs are also involved in a particular form of inflammation-induced programmed cell death, named pyroptosis. 8,9 Triggers and pathways determining cell fate upon commitment of NLRs, inflammatory state or cell death, are still incompletely understood. Nevertheless, the specific linkage between inflammasome activation and pyroptosis has been recently better clarified by the identification of gasdermin D, a protein able to form membrane pores leading to the inflammatory cell death, upon caspase-1 and caspase-11 mediated cleavage 10 (Fig. 1).

To date, four cytoplasmic PRRs able to form an inflammasome complex have been described: NLRP1, NLRP3, NLRC4 and AIM2. 1,4–6,11

NLRP1 (also called NALP1) was the first member of the NLR family to be identified. 11 It is expressed in different cell sub-types (such as monocytes, dendritic cells, granulocytes and lymphocytes) and it is activated by the anthrax lethal toxin produced by *B. anthracis*. 12

NLRP3 (also called NALP3, CIAS1 or cryopyrin) has been the most extensively studied inflammasome activator, due to the wide array of its microbial and non-microbial ligands. Bacteria (including *Staphylococcus aureus*, *Escherichia coli* and *Chlamydia trachomatis*), viral and fungal pathogens (such as *Influenza A* virus, *Candida albicans* and *Saccharomyces cerevisiae*) and parasites (such as *Schistosoma mansoni*) are known activators. Non-microbial triggers of NLRP3 include crystals (monosodium urate, cholesterol crystals, calcium pyrophosphate dehydrate, silica, alum), proteins such as β-amyloid, haptens and ultraviolet irradiation. 13

NLRC4 (also known as IPAF, CARD12 or CLAN) is mainly expressed in lymphoid tissues and gastrointestinal tract and it is activated by a more limited range of triggers. Gram-negatives bacteria (such as *Salmonella*, *Legionella*, *Shigella* or *Pseudomonas*) seem to be mostly involved in its activation. 14–16 AIM2 is the only PRR that does not belong to the NLR family receptors. It probably initiates inflammasome formation after the binding to double-stranded deoxyribonucleic acid (DNA), taking part in the cytosolic recognition of several pathogens. 17

**Caspase-1**

Caspases are a family of cysteine proteases that cleave their substrates after an aspartic acid residue. While the majority of caspases are well known for their role in the apoptotic process, a few so-called ‘inflammatory caspases’ (caspase-1, -4, -5 and -11 in humans) are important for the proteolytic activation and secretion of inflammatory mediators. 1,11,13 Caspase-1 is recruited after NLRs activation, and it is the final common pathway of inflammasome activation, involved in the proteolytic cleavage of many inflammatory mediators, such as IL-1β and IL-18, and apoptotic caspases. 18,19 In resting cells, caspase-1 is inactive; once recruited by an inflammasome platform, caspases can proteolytically activate each other; the cleavage of gasdermin D downstream of caspase-1 might provide a mechanistic link to pyroptosis. 20 Furthermore, even if inflammasome/caspase-1 pathway is classically associated to pro-inflammatory and detrimental functions, recent studies have also revealed anti-inflammatory and protective functions of caspase-1, mediating tissue healing and cell survival. 21

**Interleukin-1β**

IL-1β is the prototypic pro-inflammatory cytokine, implicated in acute and chronic inflammatory disorders and produced in response to inflammatory stimuli, such as TLR activation and other pro-inflammatory cytokines. IL-1β induces a wide range of genes, including cyclooxygenase-2, inducible nitric oxide synthase, other cytokines such as IL-6 and tumour necrosis factor (TNF), chemokines, matrix metalloproteinases (MMP) and adhesion molecules. Acting as a bone marrow stimulant, it increases myeloid progenitor cells and induces neutrophils. 21,22 IL-1β activation requires proteolytic cleavage of its inactive precursor pro-IL-1β performed by caspase-1, activated within the inflammasomes (Fig. 2).

**Inflammasome Activation: The NLRP3 Model**

NLRP3 inflammasome requires double-step activation. Under resting condition, NLRP3 protein is in a self-inhibiting state (probably mediated by leucine-rich repeat domain); substrates as pro-IL-1β, pro-IL-18, pro-caspase-1 and NLRP3 itself are not highly expressed. Any known nuclear factor-kappa B (NF-kB) activating stimulus can be an inflammasome-priming signal. 23,24 These stimuli could be both microbial, through the involvement of PRRs such as TLRs, and non-microbial, including IL-1β itself. Upon priming stimulation, substrates like NLRP3 and pro-IL-1β are transcribed but not activated. Only after a specific NLRP3 trigger (such as K+
<table>
<thead>
<tr>
<th>Family</th>
<th>Member</th>
<th>Other names and aliases</th>
<th>Tissue expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLRA</td>
<td>CIITA</td>
<td>NLRA; MHC2TA; C2TA</td>
<td>Thymic epithelium, B cells, dendritic cells, monocytes</td>
</tr>
<tr>
<td>NLRB</td>
<td>NAIp</td>
<td>NLRB1; BIRC1; CLR5.1</td>
<td>Macrophages</td>
</tr>
<tr>
<td>NLRC</td>
<td>NOD1</td>
<td>NLRRC2; CARD4; CLR7.1</td>
<td>Heart, spleen, placenta, lung and epithelium, ovary, pancreas, placenta, skeletal muscle, testis</td>
</tr>
<tr>
<td></td>
<td>NOD2</td>
<td>NLRC2; CARD15; CD; BLAUS; IBD1; PSORAS1; CLR16.3</td>
<td>Monocytes, dendritic cells, granulocytes, intestinal epithelial cells, Paneth cells</td>
</tr>
<tr>
<td></td>
<td>NOD3</td>
<td>NOD3; CLR16.2</td>
<td>Highest expression in purified T cells, B cells and NK cells, but also in thymus, uterus, kidney</td>
</tr>
<tr>
<td></td>
<td>NOD4</td>
<td>CARD12; CLAN; CLR2.1; IPAF</td>
<td>Bone marrow, macrophage, colon, kidney, liver, lung, spleen, placenta, intestine, heart (weak) and testis (weak)</td>
</tr>
<tr>
<td></td>
<td>NOD5</td>
<td>NOD27; CLR16.1</td>
<td>Macrophage, lymphocytes, immune-related tissues (bone marrow, lymph node, spleen and in PBLs), lung, small intestine, colon, uterus</td>
</tr>
<tr>
<td>NLRP</td>
<td>NLRP1</td>
<td>NALP1; DEFCAP; NAC; CARD7; CLR17.1</td>
<td>Heart, thymus, spleen, peripheral blood leukocytes, monocytes, dendritic cells, B cells and T cells, stomach, gut, neurons and testis</td>
</tr>
<tr>
<td></td>
<td>NLRP2</td>
<td>NALP2; PYPAF2; NBS1; PAN1; CLR19.9</td>
<td>Thymus, placenta and lung</td>
</tr>
<tr>
<td></td>
<td>NLRP3</td>
<td>CIA51; PYPAF1; Cryopyrin; CLR1.1; NALP3</td>
<td>Peripheral blood leukocytes, chondrocytes, monocytes, T cells, dendritic cells, oropharynx, oesophagus, ectocervix</td>
</tr>
<tr>
<td></td>
<td>NLRP4</td>
<td>NALP4; PYPAF4; PAN2; RNH2; CLR19.5</td>
<td>Highest in spleen, but also in kidney, lung, liver, placenta, thymus and pancreas</td>
</tr>
<tr>
<td></td>
<td>NLRP5</td>
<td>NALP5; PYPAF8; MATER; PAN11; CLR19.8</td>
<td>Oocytes</td>
</tr>
<tr>
<td></td>
<td>NLRP6</td>
<td>NALP6; PYPAF5; PAN3; CLR11.4</td>
<td>Epithelium, granulocytes, monocytes, T cells, B cells, eosinophils, dendritic cells (weak)</td>
</tr>
<tr>
<td></td>
<td>NLRP7</td>
<td>NALP7; PYPAF3; NOD12; PAN7; CLR19.4</td>
<td>Liver, lung, placenta, spleen, thymus, peripheral blood leukocytes, testis and ovaries</td>
</tr>
<tr>
<td></td>
<td>NLRP8</td>
<td>NALP8; PAN4; NOD16; CLR19.2</td>
<td>Ovaries, testes and pre-implantation embryos</td>
</tr>
<tr>
<td></td>
<td>NLRP9</td>
<td>NALP9; NOD6; PAN12; CLR19.1</td>
<td>Ovaries, testes, oocytes and pre-implantation embryos</td>
</tr>
<tr>
<td></td>
<td>NLRP10</td>
<td>NALP10; PAN5; NOD8; PYNOD; CLR11.1</td>
<td>Brain, heart, skeletal muscle, monocytes</td>
</tr>
<tr>
<td></td>
<td>NLRP11</td>
<td>NALP11; PYPAF6; NOD17; PAN10; CLR19.6</td>
<td>Brain, GI tract, female reproductive system, skin, lung, blood</td>
</tr>
<tr>
<td></td>
<td>NLRP12</td>
<td>NALP12; PYPAF7; Monarch1; RNO2; PAN6; CLR19.3</td>
<td>Granulocytes, dendritic cells, monocytes, leukocytes, PBMCs</td>
</tr>
<tr>
<td></td>
<td>NLRP13</td>
<td>NALP13; NOD14; PAN13; CLR19.7</td>
<td>Female reproductive system</td>
</tr>
<tr>
<td></td>
<td>NLRP14</td>
<td>NALP14; NOD5; PAN8; CLR11.2</td>
<td>Testes</td>
</tr>
<tr>
<td>NLRX</td>
<td>NLRX1</td>
<td>NOD9; CLR11.3</td>
<td>Immune cells</td>
</tr>
</tbody>
</table>

Abbreviations: GI, gastrointestinal; HGNC, HUGO Gene Nomenclature Committee; NK cells, natural killer cells; NLR, nucleotide-binding oligomerization domain (NOD)-like receptor; PBL, peripheral blood lymphocyte; PBMC, peripheral blood mononuclear cell; Note: To date, more than 20 NLRs have been described, divided in four main sub-classes based on their different N-terminal domain: NLRA (acid transactivation domain), NLRB (baculoviral inhibitory repeat [BIR]-like domain), NLRC (caspase-recruitment domain [CARD]), NLRP (pyrin domain [PYD]). The table shows the different NLRs groups and their expression in the tissues.

*aHGNC-approved symbol.*
Table 2 Receptors involved in inflammasome activation

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Approved name</th>
<th>Domain organization</th>
<th>Chromosomal location</th>
<th>Activation stimuli or microbial motifs recognized</th>
</tr>
</thead>
<tbody>
<tr>
<td>NLRP1</td>
<td>NLR family, pyrin domain containing 1</td>
<td>PYD-NACHT/NBD-LRR-FIIND-CARD</td>
<td>17p13.2</td>
<td>B. anthracis (Anthrax Lethal Toxin, in mice), MDP</td>
</tr>
<tr>
<td>NLRP3</td>
<td>NLR family, pyrin domain containing 3 (also known as NALP3, CIAS1 or Cryopyrin)</td>
<td>PYD-NACHT/NBD-LRR</td>
<td>1q44</td>
<td>Bacterial mRNA, bacterial DNA:RNA hybrids, MDP, DNA and RNA viruses, fungi, protozoa, ATP, uric acid crystals, silica, aluminium hydroxide, asbestos, bee venom</td>
</tr>
<tr>
<td>NAIP/ NLRC4</td>
<td>NLR family, CARD domain containing 4 (also known as IPAF, CARD12 or CLAN)</td>
<td>CARD-NACHT/NBD-LRR</td>
<td>2p22.3</td>
<td>Flagellin, bacterial needle and inner rod proteins from Gram-pathogens with type III or type IV secretion system (Salmonella, Legionella, Shigella, Pseudomonas), but it has been also described a flagellin-independent activation</td>
</tr>
<tr>
<td>AIM2</td>
<td>Absent in melanoma 2</td>
<td>PYD-HIN 200</td>
<td>1q22</td>
<td>Cytosolic dsDNA from virus and bacteria (such as F. tularensis, L. monocytogenes, M. tuberculosis, S. pneumoniae, CMV and vaccinia virus)</td>
</tr>
</tbody>
</table>

Abbreviations: ATP, adenosine triphosphate; CARD, caspase activation and recruitment domain; CMV, cytomegalovirus; dsDNA, double-stranded deoxyribonucleic acid; FIIND, domain with ‘function to find’; HIN 200, haemopoietic expression, interferon-inducibility, nuclear localization; LRR, leucine-rich repeat; MDP, muramyl dipeptide; mRNA, messenger ribonucleic acid; NACHT/NBD, nucleotide-binding and oligomerization domain; NAD, NBD-associated domain; NLR, nucleotide-binding oligomerization domain (NOD)-like receptor; PYD, pyrin domain.

efflux, Ca\(^{2+}\) signalling, reactive oxygen species (ROS)-induced mitochondrial dysfunction and lysosomal destabilization), the inflammasome is assembled and activated, with the subsequent cleavage and release of IL-1\(\beta\) (+ Fig. 2). Recently, the site-specific phosphorylation of NLRP3 mediated by c-Jun N-terminal kinase has been described as a key event for the subsequent inflammasome assembly.25 Specific kinases, such as double-stranded ribonucleic acid (RNA)-dependent protein kinase and Nek7 seem to be also involved in inflammasome activation.26,27 Among the non-crystalline stimuli of NLRP3, recent studies highlight a specific role of disturbed flow and hypoxia. Indeed, hypoxic human macrophages have been demonstrated to produce higher amount of IL-1\(\beta\) than normoxic macrophages28 and endothelial cells exposed to pro-atherogenic disturbed flow conditions expressed higher levels of NLRP3, caspase-1 and IL-1\(\beta\).29 Moreover, specific proteins involved in the regulation of microtubule dynamics orchestrate NLRP3 inflammasome activation, by controlling its transport to optimal activation sites.30

**Cardiovascular Disease and Inflammation: The Role of Inflammasome and IL-1\(\beta\)**

The inflammatory nature of atherosclerosis is well established but the agents that excite inflammation in the artery wall remain largely unknown.31,32 Numerous evidences suggest a pivotal role of IL-1\(\beta\) in CAD, but the relevance of inflammasome activation in each phase of atherosclerosis, from plaque formation to acute coronary syndromes (ACS) and chronic heart failure (HF), needs to be further elucidated. Both in CAD patients presenting with acute myocardial infarction (AMI) and in stable CAD patients, elevated blood levels of soluble and cell-bound members of the TNF superfamily, as well as from the IL-1 family (IL-1\(\beta\), IL-18) were detected and correlated with the subsequent risk of cardiovascular death or chronic HF.33–38

**Inflammasome and Plaque Formation**

Recent studies demonstrated that common cardiovascular risk factors such as tobacco smoking and higher body mass index positively correlate with systemic NLRP3 levels.39 Atherosclerotic arteries express higher levels of IL-1\(\beta\) and IL-1 receptor 1 (IL-1R1), as compared with normal arteries, while increased IL-1 receptor antagonist (IL-1Ra) levels are associated with reduced coronary atherosclerosis.40 The in vitro addition of IL-1\(\beta\) and TNF-\(\alpha\) to human macrophages induces increased foam cell formation, with dose-dependent retention of cholesterol and triglycerides.41 Cholesterol crystals induce secretion of IL-1\(\beta\) from human monocytes and macrophages, through the activation of NLRP3 inflammasome, while the inhibition of NLRP3 leads to a drastic reduction of IL-1\(\beta\) levels, thus identifying NLRP3 inflammasome as the cholesterol crystal-responsive element in
macrophages.\(^{42}\) Alongside, in a murine model of atherosclerosis, has been also shown that the activation of NLRP3 inflammasome by cholesterol crystals in macrophages involves lysosomal disruption and cytosolic release of cathepsin B and that cholesterol crystals themselves can form from oxidized low-density lipoproteins,\(^{33}\) with a direct link between IL-1\(\beta\) synthesis by NLRP3 in inflammasome and foam cell formation during early atherosclerosis.\(^{43}\) Recently, the CD36-mediated endocytic pathway has been identified as a master regulator of inflammasome activation in atherosclerosis. CD36 co-ordinates the intra-cellular conversion of soluble ligands, such as cholesterol or amyloid, to crystals or fibrils, resulting in lysosomal disruption and NLRP3 inflammasome activation.\(^{44}\) Moreover, atherosclerotic plaques of murine models expressed higher levels of the purinergic receptor P2X\(\gamma\), that binds extracellular adenosine triphosphate (ATP), which in turn acts as DAMP for intra-cellular sensors, promoting inflammasome activation. After high cholesterol diet, P2X\(\gamma\)-deficient mice showed smaller atherosclerotic lesions and low-grade inflammation essentially caused by caspase-1 inhibition.\(^{45}\) Furthermore, since cholesterol crystals might induce inflammasome activation in a C5a-dependent manner,\(^{46}\) a novel field of research has been focused on complement system as innate immune mediator acting synergically with surface and intra-cellular PRRs recognizing danger stimuli and modulates inflammasome activation,\(^{47}\) with both activating\(^{48}\) and inhibiting properties.\(^{49}\)

Taken together, these experiments demonstrate that cholesterol is an endogenous DAMP able to prime NLRP3 inflammasome, and its deposition in the arteries might be an early cause rather than a late consequence of the chronic inflammation leading to atherosclerosis. Nevertheless, infectious agents can represent exogenous DAMPs and exert local pro-atherogenic effects by activating NLRP3 inflammasome in almost every cellular type within the plaque. In this way, NLRP3 might represent the cornerstone in the complex relationship between infections, immune response, vascular wall damage and atherosclerosis onset and progression.\(^{50}\)

However, a lot of evidence showed opposite effects of NLRP3, ASC and caspase-1 deficiencies on atherosclerosis. An experimental study on IL1\(\beta^{-1}\)–Apo\(\text{e}^{-1}\) mice documented a surprising role of IL-1 in promoting plaque stability through the increase in smooth muscle cells and collagen content of the plaque.\(^{51}\) Another study on double knockout mice models demonstrated that the absence of NLRP3, ASC or caspase-1 does not influence atherosclerosis progression, plaque infiltration by macrophages and plaque stability.\(^{52}\)

---

**Fig. 1** Pattern recognition receptors (PRRs). Four main classes of PRRs have been described: Toll-like receptors (TLRs), retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and absent in melanoma 2 (AIM2) receptors. Whereas TLRs, expressed on cell surface and endosome’s membranes, are mostly addressed to sense microbial products (pathogen-associated molecular patterns, PAMPs), NLRs, RLRs and AIM2 function as pathogen sensors in intra-cellular compartments. As explained in the text, all PRRs recognize also a class of signals in the form of cellular stressors collectively termed ‘danger signals’ or danger-associated molecular patterns (DAMPs). The figure shows the different classes of PRRs and some of the activating stimuli, in the form of PAMPs (infectious agents, viral and bacterial deoxyribonucleic acid [DNA]/ribonucleic acid [RNA]) or DAMPs (K\(^+\) efflux through pore protein, reactive oxygen species [ROS], lysosomal damage, with the consequent release of lysosomal enzymes such as cathepsin B). RLRs are a recently discovered group of PRRs involved in viral RNA recognition in the intra-cellular space, while AIM2 are able to sense cytoplasmic double-stranded DNA. NLR family comprises a large amount of intra-cellular PRR involved in the recognition of a huge amount of exogenous and endogenous ligands.
The reason for this discrepancy is unclear and the above-mentioned notions deriving from animal studies need to be reinforced by other evidences. However, these data suggest that NLRP3 inflammasome and IL-1 might play different and sometimes opposite roles in distinct cell types during the different stages of atherosclerosis.

IL-18 expression is also increased in human atherosclerotic lesions, with expression levels significantly higher in unstable compared with stable plaques. Lack of IL-18 has been associated to a reduced atherosclerotic burden in a mouse model of atherosclerosis. Besides in vitro and animal studies, also clinical data confirmed the association of elevated IL-18 levels with cardiovascular disease risk factors.

**Inflammasome, Innate Immunity and Acute Coronary Syndromes**

Cholesterol crystals might also destabilize the plaque via NLRP3 inflammasome activation, IL-1β production and the associated local inflammatory response. In this model, plaque features are thought to be relevant, as plaques with large necrotic cores will release greater amounts of cholesterol crystals into the circulation causing more injury and arterial thrombosis. Systemically, IL-1β then induces IL-6, which elicits an acute-phase response in the liver, with the consequent release of acute-phase proteins. Among them, C-reactive protein assessed by high-sensitivity assays (hs-CRP) is typically elevated in ACS and related to prognosis. This is
not surprising as CRP is a prototypic marker of inflammation characterized by high sensitivity and a wide dynamic range.\(^61,62\) Thus, inhibition of inflammation by IL-1β antagonists or agents that dissolve or prevent cholesterol crystal formation may stabilize vulnerable plaques. In line with these evidences, a significantly higher systemic NLRP3 concentration has been shown in ACS patients, with a positive correlation with the extent of coronary atherosclerosis (assessed by different clinical scoring systems, such as SYNTAX, Clinical SYNTAX and Gensini), and with Global Registry of Acute Coronary Events and Thrombolysis in Myocardial Infarction risk score, suggesting a prognostic role of NLRP3 in ischemic patients, as an independent predictor of major adverse cardiovascular events (Major Adverse Cardiac Event [MACE], particularly 30 days’ mortality).\(^39\) Our group recently demonstrated a higher expression of NLRP3 and pro-IL1β messenger RNA (mRNA) in samples of epicardial adipose tissue obtained at the time of cardiac surgery from patients presenting with ACS as compared with stable angina and mitral valve disease patients with no overt coronary disease. Moreover, we found that the pro-inflammatory response leading to NLRP3 and pro-IL1β expression could be the direct consequence of microbial colonization of epicardial adipose tissue.\(^63\) IL-1β, IL-18 and caspase-1 are highly activated following myocardial infarction (MI) and they might substantially contribute to post-ischemic remodeling.\(^54\) On the other hand, their deficiency is associated with an increased survival following experimental MI,\(^65\) and, in an in vivo animal model of AMI, the use of an IL-18 neutralizing antibody reduces the infarct size.\(^66\)

The notion that innate immunity plays an important role in ACS is supported by the demonstration of activated monocytes, polymorphonuclear neutrophils (PMNs), eosinophils and mast cells not only at the site of plaque rupture, but also in the whole coronary circulation of patients with ACS.\(^67\) A high telomerase activity in PMNs coming from the culprit coronary plaque of patients with ACS has been demonstrated. This might represent a way to overcome replicative senescence, resulting in a prolonged survival and toxic potential of these inflammatory cells.\(^68\) Accordingly, we have shown a delayed apoptosis of peripheral PMNs in ACS patients.\(^69\) The role of PMNs has been further clarified in studies highlighting the prominent role of these cells in plaque instability: high levels of PMN-related biomarker myeloperoxidase has been associated with atherosclerosis and ACS.\(^67,70\) and several experimental models suggested a key role of this cell sub-set in plaque destabilization through endothelial erosion.\(^71\)

Macrophages account for the majority of leukocytes in plaques. Most of plaque resident macrophages differentiate from monocytes recruited from circulating blood. However, monocytes represent a heterogeneous circulating population of cells, accordingly to their differential expression of CD14 and CD16.\(^72\) Human coronary artery lesions contain macrophage sub-populations with different gene expression patterns, which indicate heterogeneity. The canonical classification derived from in vitro studies states that this cell population can be functionally divided into two distinct groups, a pro-inflammatory phenotype, M1, involved in pro-inflammatory cytokines production and Th1 lymphocytes commitment, and M2 macrophages, with pre-eminence phagocytic activity, that mostly participate to tissue healing and inflammation dampening.\(^73\) Patients with coronary atherosclerosis have higher numbers of circulating CD14\(^+\)CD16\(^+\) monocytes than healthy subjects and peak levels of CD14\(^+\)CD16\(^-\) monocytes after AMI negatively correlate with the recovery of left ventricular ejection fraction (LVEF) 6 months after MI.\(^74\) Fluorescence-activated cell sorting analysis of coronary thrombi obtained during primary percutaneous coronary intervention (pPCI) revealed a greater proportion of CD14\(^+\) cells in thrombi as compared with aortic blood. Moreover, monocytes accumulated within thrombi specifically over-express TLR-4, together with specific patterns of locally expressed chemokines and cytokines as compared with circulating monocytes.\(^75\) Interestingly, interferon (IFN)-α, produced by dendritic cells in atherosclerotic plaques, could enhance TLR-4 signalling by sensitizing these cells to lipopolysaccharides and other microbial molecules but also to modified endogenous molecules, all abundantly present in the atherosclerotic lesion micro-environment. These sensitized APCs strongly up-regulate the production of cytokines such as TNF-α, IL-12, IL-23 and MMP-9, thus enhancing plaque instability.\(^76\)

**Inflammasome, Innate Immunity and Post-Infarction Remodelling**

It is well recognized that maladaptive ventricular remodelling, leading to HF, can be a consequence of a dysregulated inflammatory process. Cardiac fibroblasts are the most represented cell population in the heart and their role is not only confined to myocardial fibrosis. By releasing pro-inflammatory cytokines in response to danger signals, they might modulate the crosstalk between innate immune system and surrounding cells, including cardiomyocytes, vascular cells and peripheral inflammatory cells.\(^77\) NLRP3, IL-1β and IL-18 mRNA expression levels are significantly up-regulated in myocardial fibroblasts of adult mice following infarction, suggesting that NLRP3 inflammasome is one of the key mediators of myocardial ischemia/reperfusion (I/R) injury and infarct size.\(^78\) NLRP3 inflammasome is one of the major cytosolic danger sensors in cardiomyocytes, and endogenous IL-1β and IL-18 play a significant role in I/R-induced human myocardial injury.\(^79\) Indeed, caspase-1 inhibition prevents ischemia-induced myocardial dysfunction in in vitro models of human atrial myocardium.\(^80\) Patients with ischemic HF have increased IL-18 circulating levels that positively correlate with a worse outcome.\(^81\) Moreover, a correlation between infarct size, inflammasome activation and IL-1β production during myocardial I/R injury has been demonstrated in vivo, together with the reduction of infarct size after I/R in mice after the administration of NLRP3 inflammasome inhibitors.\(^82,83\) Several mechanisms are involved in NLRP3 inflammasome activation in failing cardiac fibroblasts: ATP-induced K⁺ efflux, translocation of mitochondrial DNA (from the nucleus to
the cytoplasm) and production of ROS. Mitochondrial integrity in cardiac cells seems to be the key limiting factor of inflammasome activation, since a defective intra-cellular clearance of damaged mitochondria could be responsible of NLRP3 inflammasome up-regulation in failing cardiomyocytes. On the other hand, it is well known that IL-1β has a direct effect as a ‘myocardial depressant factor’, able to directly impair myocardial contractility and relaxation through different mechanisms, such as calcium-channel inhibition, uncoupling of β-adrenergic receptors from the adenylyl cyclase, down-regulation of phospholamban and sarco/endoplasmic reticulum Ca2+-ATPase and nitric oxide synthase-enhanced expression. A very recent work by van Hout et al demonstrated that pigs undergoing balloon coronary occlusion and subsequent treatment with a specific NLRP3 inhibitor showed a smaller infarct size, a markedly preserved ejection fraction and a lower neutrophil influx as compared with non-treated animals, thus confirming the detrimental effects of IL-1β and IL-18, whose levels were also dose-dependently reduced in treated pigs.

According to this ‘inflammatory hypothesis’, modulation of the inflammasome may therefore represent a therapeutic strategy to limit cell death and prevent HF after AMI. At this regard, it is also of interest that other members of the IL-1 family, such as IL-33, might have instead cardioprotective role in the infarct healing, by promoting dendritic cells and M2 macrophages activity and by inhibiting myocytes apoptosis. IL-33, differently from IL-1 and IL-18, is biologically active in its full-length form of 31 kDa and its production is independent from inflammasome activation; however, caspase-1 seems to be involved in the cleavage of this molecule leading to the release of an inactive form. Thus, a more profound comprehension of these pathways will probably allow to modulate, through specific therapeutic tools, inflammasome and caspase activity towards cardioprotective routes.

Adaptive Immunity in Cardiovascular Disease

The presence of leucocytes within the atherosclerotic plaque was demonstrated in the late 1970s, after the discovery of lipid-laden foam cells derived from macrophages in the same site. The detection of human leucocyte antigen molecules in plaques and the subsequent discovery of T cells some years later suggested that cellular immune responses in the vessel wall could be also possibly involved in atherogenesis and in the progression of the disease. Around 70% of T lymphocytes populating atherosclerotic plaques are CD4+ T-helper (Th) cells. Most of these cells belongs to type 1 pro-inflammatory Th1 sub-set and expresses pro-atherogenic cytokines such as IFN-γ and TNF.

T-Lymphocytes and Plaque Formation

The importance of Th1 cells in atherosclerosis has been documented in several studies, both in experimental animal models and in humans. Absence of CD4+ Th cells, deficiency of Th1-cytokine INFγ or deletion of the Th1 transcription factor T-bet in mice leads to reduction in plaque size and atherosclerotic burden. Conversely, the role of Th2 sub-set and its related cytokines in atherosclerosis is still controversial, with both pro-atherogenic and protective effects documented. Recently, the Th1/Th2 paradigm of Th cell differentiation has been expanded following the discovery of CD4+CD25+ regulatory T cells (Tregs) and effectors Th cells producing IL-17 (Th17), described as two distinct lymphocyte sub-sets. Overall, the former exhibit immunosuppressive properties and represent the master modulators of inflammatory responses, while Th17 seem to have mainly a pro-atherogenic role; nevertheless, an atheroprotective function has been recently documented. Tregs are found in affected arteries wall, representing approximately 1 to 5% of the localized T cell population within atherosclerotic plaque. Impairment in number or function of Tregs could induce plaque formation and progression of atherosclerotic disease. In other studies, apolipoprotein E (ApoE)−/− mice showed increased atherosclerotic lesion size and increased vulnerability after the depletion of peripheral Tregs by anti-CD25 monoclonal antibodies. Conversely, a decreased size of atherosclerotic lesions in ApoE−/− mice receiving adoptive transfer of Tregs has been shown compared with ApoE−/− mice treated with phosphate buffer saline or effector T cells. Anti-atherogenic effects have been also showed for Tregs’ hallmark cytokines transforming growth factor (TGF)-β and IL-10.

Th17 lineage, expressing RORyt as transcription factor, differentiates from naïve CD4+ T cells upon TGF-β, IL-23 and IL-6 stimulation. IL-17, primarily produced by Th17, induces pro-inflammatory cytokines release and neutrophils mobilization. The role of Th17 lymphocytes in atherosclerosis remains controversial. Increased levels of Th17 and Th17-associated cytokines, such as IL-17, IL-21 and IL-23, have been described in atherosclerotic carotid artery plaques and have been associated with the progression of atherosclerotic disease and with plaque vulnerability. Other studies reported that patients with ACS showed a significant increase in peripheral Th17 cells, Th17-related cytokines and iROR-γt expression, as compared with stable angina (SA) patients and healthy controls. The increase in circulating levels of Th17 paralleled a reduction in peripheral Tregs, Treg-related cytokines and forkhead box P3 (FoxP3) expression. However, some recent studies reported different outcomes. Taleb et al documented an association between IL-17 expression in human carotid artery plaques and plaque stability. Brauner et al have recently confirmed these data by demonstrating that IL-17 is linked to increased collagen content in atherosclerotic plaque. More recently, lower levels of circulating IL-17 have been associated with a worse outcome at 2 years' follow-up in a large population of patients admitted for AMI. A mechanistic explanation for these discrepancies is still lacking; however, the controversial results of the above-mentioned studies could be at least in part explained by the astonishing flexibility of Th17 sub-set.
T-Lymphocytes and Acute Coronary Syndromes

Overall, about half of patients with ACS and systemic evidence of inflammation have a skewed T cell differentiation oriented towards aggressive effector phenotypes and defective Tregs. In this sub-set of ACS patients, helper T cell dysregulation might affect the biological outcome of the immune response and contribute to plaque destabilization through multiple damaging pathways. In ACS patients, helper T cell abnormalities are associated with worse outcomes, especially in patients with diabetes mellitus. Moreover, CD4+ T-cells from ACS patients show enhanced response to T cell receptor (TCR) stimulation and have a lower setting of the T cell activation threshold, attributable to enhanced amplification of proximal TCR-mediated signals. Intriguingly, some of these abnormalities are confined to the acute phase of ACS, whereas others persist during the stable phase of the disease, suggesting the existence of a deep-seated lymphocyte hyper-reactivity that may abruptly degenerate to cause an inflammatory outburst. The molecular TCR signalling alterations observed in ACS include an increase in the positive activation signals with higher accumulation of CD3 complexes and zeta-chain associated protein kinase of 70 kD (Zap70) in the immunological synapse during antigen presentation, higher early tyrosine phosphorylation after TCR stimulation and a defective deactivation of the lymphocyte-specific protein tyrosine kinase (LCK). On the other hand, ACS patients exhibit reduced activity of the inhibitory molecular patterns such as reduced phosphorylation of Zap70 at its inhibitory residue Tyr-292, lower expression of PECAM-1, a molecule implicated in down-modulation of T cell activity and reduced activation of cyclic adenosine monophosphate response element binding, a transcription factor believed to be particularly important for the generation and maintenance of Treg and for IL-2 and IL-10 production. Finally, ACS patients show enhanced expression of the protein tyrosine phosphatase non-receptor type 22, an enzyme playing a key role in controlling the intensity of the early TCR signal transduction acting on LCK and on Zap70. Overall, the lower setting of T cell activation threshold could affect the direction of T cell differentiation leading to the unbalanced helper T cell subset expansion observed in ACS patients.

IL-1, Innate-Adaptive Immunity Crosstalk and Cardiovascular Disease

In immune response, the innate recognition of an altered homeostasis (tissue damage, infections) is the first step to generate an effective adaptive immunity. Understanding the crosstalk between the two arms of immune response represents a crucial point to explain the pathophysiology of chronic inflammatory and autoimmune diseases. Recent evidences described a possible role of inflammasome in providing instruction to the adaptive immune system, and even if IL-1 represents only one of multiple factors required for mounting effective lymphocytes activation, its role on specific CD4+ T cell sub-set has become recently more clear. Animal models demonstrated that lymphocyte sensitization was dampened in inflammasome-deficient mice. It has also been shown that ATP released by dying tumour cells activates NLRP3 in dendritic cells, and the release of IL-1β is sufficient to drive an adaptive anti-tumour immunity. Several studies explored the crosstalk between inflammasome and T cell responses in autoimmune disease, with conflicting results. Very recently, a direct role for NLRP3 in human adaptive immune cells has been described, as it has been shown that NLRP3 inflammasome assemblies in human CD4+ T cells and initiates caspase-1-dependent IL-1β secretion, thereby promoting IFN-γ production and Th-1 differentiation in an autocrine manner. Aberrant NLRP3 activity in T cells affects inflammatory responses in human auto-inflammatory disease and in mouse models of inflammation and infection. Together, these data demonstrate that human CD4+ T cells produce IL-1β in an NLRP3-dependent manner, autocrine IL-1β generation supports IFN-γ secretion and dysregulation of this pathway occurs in human auto-inflammatory disease. Thus, NLRP3 inflammasome activity is not confined to ‘innate immune cells’ but is an integral component of normal adaptive Th1 responses. Given the ability of IL-1β and inflammasome in driving adaptive immunity responses, it is conceivable that a similar crosstalk could be involved in CAD as well. An altered adaptive immune response is indeed one of the hallmarks of CAD. The exact role of IL-1β and inflammasome in providing instruction to the adaptive immune system in the specific setting of atherosclerosis, from plaque formation to ACS, needs to be further elucidated in targeted studies. However, a wide amount of evidences demonstrates an imbalance in T cell sub-sets both in stable CAD and in ACS on one hand (see above), and a crucial role of IL-1β in inducing the differentiation of T cell sub-sets towards those phenotypes expanded in CAD, on the other hand (Fig. 3).

As described for other inflammatory and autoimmune diseases, the imbalance of adaptive immunity found in atherosclerosis can be at least in part explained by different environmental conditions leading to inappropriate effector T cells activation and impaired Tregs number and/or function. T lymphocytes show a great degree of flexibility, and robust evidences widely demonstrated that their differentiation is strictly dependent on the balance between polarizing cytokines rather than on their absolute amount. In the context of atherosclerosis, it is possible that IL-β may act directly in target tissues, such as vessel wall and atherosclerotic plaque, increasing T cell activity in synergy or antagonism with other factors known to modulate inflammation. A higher expression of inflammasome-related genes has been described in CD4+CD28null T cells, a long-lived Th1 cell sub-set characterized by an aggressive effector phenotype and associated with worse outcomes in ACS. This represents a pre-activation state that leads to an increased release of IL-1β upon cell activation and contributes to the functional properties of CD4+CD28null T cells. IL-1β through IL-1R signalling can provide a survival signal to naïve T cells, causing a transient release of the survival cytokine IL-2 from T cells and up-regulating IL-2R surface expression. Furthermore, IL-1β is actively involved in...
Innate-adaptive immunity crosstalk and plaque instability. Around 70% of T lymphocytes populating atherosclerotic plaques are CD4+ T-helper cells. Most of these cells belong to type 1 pro-inflammatory T-helper (Th1) sub-set and expresses pro-atherogenic cytokines such as interferon-γ (IFN-γ) and tumour necrosis factor (TNF-α). Regulatory T cells (Tregs) exhibit immunosuppressive properties and represent the master modulators of inflammatory responses, with a prevalent anti-atherogenic effect (interleukin (IL)-10 and transforming growth factor (TGF)-β production). Th17 seem to have mainly a pro-atherogenic role; however, an atheroprotective function has been also recently documented. This might be a direct consequence of the flexibility of Th17 cell lineage: indeed, in different environmental circumstances the maintenance of CD4+ memory T cells and in the interaction between T- and B-lymphocytes, with the subsequent production of high-affinity antibodies. IL-1β signalling allows for a breach in tolerance through expansion of conventional T cells even in the presence of Tregs. Recent studies indicate that IL-1β plays a critical role in early Th17 cell differentiation. Sutton et al showed that IL-1 receptor expression in T cells, induced by IL-6, is necessary for the induction of experimental autoimmune encephalomyelitis and for early Th17 cell differentiation in vivo. Moreover, CD4+ T cells primed by NLRP3-activated antigen presenting cells up-regulate chemotaxis-related proteins (such as CCR2 and CXCR6), resulting in T cell migration in the same model of experimental autoimmune encephalomyelitis. Increased levels of Th17 in IL-1Rα−/− mice have been demonstrated, with the consequent development of rheumatoid arthritis, suggesting that IL-1 is the driving force behind the IL-17-producing Th17 cells. In human immune system, Th17 cells can shift to a Th17/Th1 phenotype upon specific stimulation by IL-1β. The presence of IL-17/IFN-γ dual producing cells, expressing T-bet and RORγt transcription factors has been described within atherosclerotic plaque, together with a synergistic pro-inflammatory effect of IL-17 and IFN-γ on vascular wall. Moreover, upon T cell stimulation in the presence of pro-inflammatory cytokines, such as IL-1β, IL-2, IL-21 and IL-23, Tregs can differentiate into IL-17 producing cells, expressing RORγt and FoxP3 transcription factors. The exact role of IL-17 producing Tregs in the setting of atherosclerotic disease is still not clear; however, they seem to be involved in controlling the Th17/Treg balance, which is altered in atherosclerosis and even more in ACS. Mercer et al pointed out a higher expression of the inflammatory cytokine receptors IL-1R1 and high levels of mRNA for IL-1Ra on resting mature Tregs compared with naïve or memory T cells. Moreover, they found that the decoy receptor for IL-1 (IL-1R2), that specifically binds IL-1 and reduces its activity, is not expressed by any of the resting T cells but is rapidly up-regulated and preferentially expressed on Tregs upon TCR stimulation. These data prove a direct role of Tregs in dampening effector T cell activation and pro-inflammatory responses through the attenuation of IL-1β activity. The involvement of inammmasome in the crosstalk between innate and adaptive immunity is also suggested by the immune properties of IL-18. This cytokine is able to induce IFN-γ production in Th1 and natural killer cells, to activate NF-kB and to increase Fas ligand and chemokine expression. As IFN-γ inducing factor, IL-18 is involved in the activation of macrophages, in the induction of class I and II major
histocompatibility complex molecules and in Th1 cell polarization, thus representing a strong regulator of the adaptive immune response.\textsuperscript{134}

IL-1β significantly affects the cross-talk between blood platelets and the immune response system, primarily inducing the formation of blood platelet-leukocyte aggregates. Megakaryocyte maturation and RNA production are altered by IL1β and IL1R1. Platelet function is enhanced through p38 mitogen-activated protein kinase signalling pathway on IL1β stimulation. In particular, IL1β and IL1R1 increase platelet adhesion and heterotypic aggregate formation both in the setting of inflammation, high fat diet and bacterial infection, which are reversed in IL1R1\textsuperscript{-/-} and IL1β\textsuperscript{-/-} mouse models. Therefore, IL1β, through IL1R1, promotes pro-inflammatory functions in both megakaryocytes and platelets that may contribute to the development of atherothrombotic diseases.\textsuperscript{135}

**Targeting Inflammasomes in Cardiovascular Disease: State of the Art**

The involvement of NLRP3 inflammasome in a wide range of diseases makes this intra-cellular platform a desirable molecular target. To this end, several pharmacological NLRP3 inflammasome inhibitors have been tested in murine models, including small-molecule inhibitors (such as β-hydroxybutyrate), autophagy inducers agents (resveratrol and others) and microRNA (miR-223). All these agents are able to inhibit NLRP3 complex activation at different levels of inflammasome assembly. However, to date, only type 1-IFN (α and β) have been approved in clinical practice for the treatment of specific autoimmune and auto-inflammatory disease.\textsuperscript{136} As shown above, since IL-1 represents the final mediator of NLRP3 inflammasome activation, this cytokine has been widely investigated as molecular target to prevent or dampen its detrimental effects in CAD.\textsuperscript{137,138}

To date, IL-1 blocking drugs approved by Food and Drug Administration are: anakinra, a recombinant human IL-1Ra, able to inhibit both IL-1α and IL-1β; rilonacept, a recombinant fusion protein able to bind both soluble IL-1α and IL-1β and IL-1R; and canakinumab, a specific monoclonal IL-1β antibody that bind irreversibly to circulating human IL-1β and prevents activation of the IL-1 receptor, without interfering with IL-1α activity. Table 3 presents an overview of the principal clinical trials.

The MRC-ILA-HEART study was a double-blinded, placebo-controlled trial in which 186 patients with non-ST-elevation MI were recruited within 48 hours of symptom onset and randomly assigned to anakinra 100 mg subcutaneous daily or placebo for 14 days. Even if the primary endpoint of the study was reached (a statistically significant reduction of hs-CRP levels within the first week), anakinra treatment did not demonstrate to reduce troponin T levels and to influence infarct size. Conversely, this therapy was associated with increase in MACE at 12-month follow-up.\textsuperscript{139}

Intriguingly, Abbate et al obtained conflicting results in two previous small pilot studies: the Virginia Commonwealth University-Anakinra Remodeling Trial (VCU-ART) and VCU-ART2.\textsuperscript{140,141} These studies included a total of 40 patients, admitted to the coronary care unit for ST-elevation MI (STEMI), undergoing pPCI, and randomly assigned to anakinra 100 mg daily or placebo for 14 days. Anakinra-treated patients experienced no MACE, demonstrating an acceptable safety profile of this drug. Moreover, the treatment in patients with re-perfused STEMI was associated with a significant blunting of inflammatory response (significant reduction in CRP levels), with a more favourable left ventricular remodelling on cardiac magnetic resonance imaging (trend), and with a reduced rate of new-onset HF at 3 months. No differences in infarct size and in recurrence of ACS were detected in anakinra-treated patients.\textsuperscript{142} These promising findings were consistent with those obtained in previous pre-clinical murine models\textsuperscript{143} and paved the way for additional clinical trials aimed to further elucidate the IL-1 targeting in the setting of ACS. To this end, the VCU-ART3 trial is an on-going phase II study\textsuperscript{144} in which 99 patients with re-perfused STEMI will be enrolled and randomly assigned to standard (100 mg daily) versus high dose (100 mg twice daily) of anakinra, with a 1-year follow-up.

In the setting of ACS, increased soluble IL-1 plasma levels can be detected and might be involved in the maladaptive ventricular remodelling leading to HF. Ikonomidis et al in 2008 demonstrated the beneficial effect of blocking IL-1 on the entire cardiovascular system. A total of 23 patients with rheumatoid arthritis without HF were subjected to a single injection of anakinra (150 mg). A significant improvement in parameters of myocardial contractility (left ventricular function) and relaxation (E/E’ ratio), coronary flow reserve (assessed by echocardiography) and endothelial function (measured by brachial artery flow-mediated dilatation) was observed within 3 hours of the administration of anakinra and after 1 month of follow-up. A parallel group of patients treated with trimcinolone experienced no analogue beneficial effects.\textsuperscript{144}

The Acute Inflammatory Response in Heart Failure trial was an open-label, single arm pilot study in which 7 patients with HF with reduced ejection fraction (LVEF < 40%) and high levels of inflammatory markers (CRP > 2 mg/L) were enrolled and treated with anakinra 100 mg daily for 14 days. IL-1β blocked treatment lead to a significant improvement in exercise capacity, assessed by cardiopulmonary test at baseline and after 14 days of treatment. Moreover, a significant blunting of inflammatory markers was documented, with a reduction of CRP and IL-6 levels of 84% and 90%, respectively.\textsuperscript{145}

The Diastolic Heart Failure Anakinra Response (D-HART) trial is a recent pilot study based on the hypothesis that blocking IL-1β pathway might produce beneficial effects also in patients with HF with preserved ejection fraction. A 14-day treatment with anakinra 100 mg daily in a cohort of 12 patients was associated with a significant improvement in exercise capacity, assessed by peak of oxygen consumption at cardiopulmonary test, and with a significant reduction of CRP plasmatic levels.\textsuperscript{146} More recent phase II clinical trials on this field, such as the completed RED-HART trial\textsuperscript{147} and the D-HART2 trial,\textsuperscript{148} will probably provide an important contribution in the treatment of HF.
<table>
<thead>
<tr>
<th>Study</th>
<th>State of the trial</th>
<th>Study population (n)</th>
<th>Study design (regimen)</th>
<th>End points and results</th>
</tr>
</thead>
</table>
| MRGILA-HEART Study, 2014 | Completed          | NSTEMI (186)         | Anakinra 100 mg subcutaneous daily vs. placebo for 14 d | -Primary end point: area-under-the-curve for hs-CRP over the first 7 d  
-Results: reduction of hs-CRP levels within the first 7 d of treatment in anakinra-treated patients but significant increase in MACE at 12-mo follow-up |
| VCU-ART, 2010         | Completed          | STEMI (10)           | Anakinra 100 mg subcutaneous daily vs. placebo for 14 d after pPCI | -Primary end point: changes in LV remodelling (LVESVi) assessed on CMR imaging at 10- and 14-wk follow-up  
-Secondary end points: changes in LVEDVi and hs-CRP levels  
-Results: favourable post-infarction LV remodelling in anakinra-treated patients with positive correlation with hs-CRP plasmatic levels reduction |
| VCU-ART2, 2013        | Completed          | STEMI (30)           | Anakinra 100 mg subcutaneous daily vs. placebo for 14 d after pPCI | -Primary end point: changes in LV remodelling (LVESVi) assessed on CMR imaging at 10- and 14-wk follow-up  
-Secondary end points: changes in LVEDVi, LVEF and CRP levels  
-Results: significant blunting of the acute inflammatory response; failure in showing a statistically significant effect on LV remodelling (LVESVi, LVEDVi, LVEF); anakinra-treated patients experienced a numerically lower incidence of heart failure |
| VCU-ART3, 2014        | On-going           | STEMI (99)           | Anakinra standard dose (100 mg daily) vs. high dose (100 mg twice daily) vs. placebo for 14 d | -Primary end point: area-under-the-curve for hs-CRP during the first 14 d  
-Secondary end points: LV remodelling (LVESVi and LVEF) and new-onset of HF |
| Ikonomidis et al, 2008 | Completed          | Rheumatoid arthritis without HF (23) | Anakinra 150 mg single injection or placebo, and after 48 h alternative treatment | -Primary end point: effects on myocardial contractility (LVEF) and relaxation (E/E’), coronary flow reserve (CFR) and endothelial function (FMD) within 3 h and after 1 mo follow-up  
-Results: improvement in all parameters in anakinra-treated patients; a parallel group treated with prednisolone experienced no analogue beneficial effects |
| CANTOS, 2017          | Completed          | Stable post-myocardial infarction patients with | Canakinumab (50, 150 or 300 mg every 3 mo) vs. placebo | -Composite primary end point: non-fatal MI, non-fatal stroke, cardiovascular death  
-Results: at a median follow-up of 3.7 y, |

(Continued)
Table 3 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>State of the trial</th>
<th>Study population (n)</th>
<th>Study design (regimen)</th>
<th>End points and results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>residual inflammatory risk (17,200)</td>
<td>canakinumab showed a 15% reduction in the risk of the primary composite endpoint along with a 39% reduction from baseline in hs-CRP and without any effect on cholesterol. Patients treated with canakinumab also were 30% less likely to undergo percutaneous coronary intervention or coronary artery bypass graft during follow-up.</td>
<td></td>
</tr>
<tr>
<td>Setting: Heart failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIR-HF, 2012145</td>
<td>Completed</td>
<td>HfREF (7)</td>
<td>Anakinra 100 mg daily for 14 d</td>
<td>-Primary end point: effect of anakinra on cardiopulmonary exercise performance (peak VO2 and VE/VCO2 slope) between baseline and 14 d -Results: significant improvement in exercise capacity and significant blunting of inflammatory biomarkers</td>
</tr>
<tr>
<td>D-HART, 2014146</td>
<td>Completed</td>
<td>HfEF (12)</td>
<td>Anakinra 100 mg daily for 14 d</td>
<td>-Primary end point: placebo-corrected difference in the interval change in peak VO2 from baseline to follow-up -Results: significant improvement in peak VO2 and significant reduction in plasma hs-CRP levels in anakinra-treated patients; reduction in hs-CRP correlated with improvement in peak VO2</td>
</tr>
<tr>
<td>RED-HART, 2017147</td>
<td>Completed</td>
<td>HfREF (60)</td>
<td>Anakinra 100 mg daily for 2 wk (short treatment) or 12 wk (long treatment) vs. placebo</td>
<td>-Primary end point: placebo-corrected interval changes in peak VO2 and ventilatory efficiency (VE/VCO2 slope) after 2 wk of anakinra treatment -Results: no significant change in peak VO2 and VE/VCO2 slope after 2 wk of anakinra treatment; improvement in peak VO2 in patients continued on anakinra for 12 wk</td>
</tr>
<tr>
<td>D-HART2, 2014148</td>
<td>Completed, not yet published</td>
<td>HfEF (60)</td>
<td>Anakinra 100 mg daily for 12 wk vs. placebo</td>
<td>-Primary end point: aerobic exercise capacity (peak VO2) and ventilatory efficacy (VE/VCO2 slope) at 4 wk in anakinra-treated patients vs. placebo -To treat patients with HFpEF and evidence of systemic inflammation with an IL-1 blocker, anakinra to determine effects on exercise capacity measured as peak oxygen consumption at maximal cardiopulmonary exercise testing</td>
</tr>
</tbody>
</table>

Abbreviations: CMR, cardiac magnetic resonance; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HfREF, heart failure with reduced ejection fraction; hs-CRP, high sensitivity C-reactive protein; LVEDVi, left ventricle end-diastolic volume index; LVEF, left ventricle ejection fraction; LVESVi, left ventricle end-systolic volume index; NSTEMI, non-ST elevation myocardial infarction; peak VO2, peak of oxygen consumption; pPCI, primary percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; VE/VCO2 slope, minute ventilation/carbon dioxide production slope.
Despite the potential exciting clinical implications of the above-mentioned studies, the greater part of them is underpowered due to the relative small number of recruited patients. This point might explain at least in part confounding or inconclusive results.

Besides these, the results of Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial have been recently released. CANTOS is a phase III, randomized, placebo-controlled trial aimed at evaluating the potential additional beneficial role of IL-1β inhibition for the prevention of recurrent cardiovascular events among patients with stable CAD who remain at high vascular risk due to persistent elevated hs-CRP levels. At a median follow-up of 3.7 years, canakinumab at 150 and 300 mg once every 3 months showed a 15% reduction in the risk of the primary composite efficacy endpoint of non-fatal MI, non-fatal stroke or cardiovascular death, compared with placebo-treated patients, along with a 39% reduction from baseline in hs-CRP levels, without any effect on cholesterol. Patients treated with canakinumab also were 30% less likely to undergo PCI or coronary artery bypass graft during follow-up. In a secondary analysis of CANTOS trial, Ridker et al found that trial participants randomized to canakinumab who achieved hs-CRP concentrations ≤ 2 mg/L had a 25% reduction in MACE and a 31% reduction in cardiovascular mortality and all-cause mortality, whereas no significant benefit was observed among on-treatment patients with hs-CRP concentrations of 2 mg/L or above. Even if the beneficial effects of canakinumab administration needs to be examined alongside with the increased risk of infection of patients undergoing such powerful anti-inflammatory treatment, these data provide the first proof that inflammation inhibition in the absence of lipid lowering can improve CAD outcomes, thus moving the inflammatory hypothesis of CAD forward scientifically.

**Conclusion and Future Perspectives**

Robust evidences support the inflammatory nature of atherosclerosis. Based on several data, atherosclerosis could be considered as a consequence of an altered innate-adaptive crosstalk, rather than an inflammatory disease in which the two arms of immunity act separately and in different moments. In this setting, inflammasome activation, resulting from the recognition of a large variety of stimuli, is a pivotal mechanism of innate immunity leading to quantitatively and/or qualitatively inappropriate elicitation of adaptive responses within the vascular wall. According to this intriguing hypothesis, inflammasome activation, as an early, non-specific but strong response, could be seen as the common pathway on which a huge number of endogenous and external stimuli implicated in atherogenesis may converge.

Studies on the early plaques demonstrated an involvement of inflammasome from the first phases of plaque formation, showing how the deposition of cholesterol crystals in the artery wall and the consequent NLRP3 activation, might be considered as an early cause, rather than a late consequence of chronic inflammation. In the same way, inflammasome activation triggered by various infectious agents or other cell-damaging stressors could be an early step in plaque progression. The hypothesis that inflammasome activation is also involved in atherothrombosis and ACS needs to be confirmed in targeted studies, while increasing evidences from clinical studies highlights a pivotal role of IL-1 in the adverse cardiac remodelling after an AMI.

This hypothesis recently received an important proof-of-concept thanks to the results of the first mega-trial on anti-inflammatory treatment with canakinumab (CANTOS), a human monoclonal antibody against IL-1β, in patients with previous MI and ‘residual inflammatory risk’, as documented by persistently high hs-CRP levels. Nevertheless, the demonstrated absolute clinical benefit of canakinumab cannot justify its routine use in patients with previous MI and residual inflammatory risk, identified as hs-CRP ≥ 2 mg/L, until we understand more about the mechanisms responsible for coronary instability, the efficacy and safety trade-offs and unless a formal cost-effectiveness evaluation supports it.

Many different stimuli have been studied in relationship with atherosclerotic plaque formation and instability, each of them probably accounting for a small part of the process or relevant for a subset of CAD patients only. Given the epidemiologic burden of atherosclerotic disease, the individuation of key mechanisms of atherosclerosis onset and progression is of paramount importance; in this setting, further studies on early innate response and the innate-adaptive crosstalk may provide essential information on the pathogenesis of the disease, and may help individuating therapeutic tools to delay the chronic progression and prevent the acute destabilization of atherosclerotic plaque.

**Funding**

This work was partially supported by the Catholic University of the Sacred Heart, Rome, Italy [Grant R4124500186 LINEA D.1 2014 and Grant R4124500458 LINEA D.1 2016].

**Conflict of Interest**

None.

**References**

Biasucci LM, Liuzzo G, Giubilato S, et al. Delayed neutrophil...


130 Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 2003; 100(10): 5986–5990
133 Mercer F, Kozhaya L, Unutmaz D. Expression and function of TNF and IL-1 receptors on human regulatory T cells. PLoS One 2010; 5(01): e8639
134 Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103(1 Pt 1): 11–24
143 Available at: http://clinicaltrials.gov; (NCT01950299) Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3). Accessed June 20, 2018
147 Van Tassell BW, Canada J, Carbone S, et al. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail 2017; 10(11): pii: e004373
148 Available at: http://clinicaltrials.gov (NCT02173548). Accessed June 20, 2018
150 Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2018; 391(10118): 319–328